SPOTLIGHT: Erbitux fails pancreatic cancer study


ImClone's efforts to expand the use of Erbitux ran into an obstacle today as researchers reported that the drug failed a study on pancreatic cancer survival. Shares of ImClone tumbled more than 11 percent on the news. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.